CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Infusion of autologous CIK cellsprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00394381
NCT00394381Phase 2Completed
CompareCT.gov

Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Singapore General Hospital·interventional·Posted Nov 1, 2006·Updated Feb 10, 2017

In Brief

A Phase 2 clinical trial evaluating Infusion of autologous CIK cells for Acute Myeloid Leukemia and Myelodysplastic Syndrome, High Grade. Completed, enrolled 17 participants across 1 site.

Detailed Summary

A phase I/II study to explore the feasibility and efficacy of autologous CIK cells in patients with acute myeloid leukemia (AML)/ high grade myelodysplastic syndrome (MDS) 1. Group 1: As adjuvant therapy in minimal residual disease state after autologous PBSCT. 2. Group 2: As an adoptive immunotherapy in untreated disease state when conventional therapy with curative intent is not applicable

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia, Myelodysplastic Syndrome, High Grade
CountriesSingapore
CollaboratorsNational Medical Research Council (NMRC), Singapore

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 1, 2006
Enrollment StartOct 1, 2006
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.7 years ago

Interventions

Infusion of autologous CIK cellsprocedure

Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients